|
Market Closed -
Nasdaq
16:00:00 2026-08-24 EDT
|
5-day change | 1st Jan Change | ||
| 40.57 USD | +0.47% |
|
-3.22% | +49.37% |
Company Valuation: Celldex Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,803 | 2,099 | 2,169 | 1,677 | 1,805 | 3,186 | - | - |
| Change | - | 16.42% | 3.32% | -22.7% | 7.65% | 76.53% | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,794 | 1,745 | 951.2 | 1,286 | 2,524 | 2,548 | 2,591 |
| Change | - | 28.64% | -2.73% | -45.5% | 35.21% | 96.21% | 0.98% | 1.65% |
| P/E | -23.6x | -18.6x | -13.6x | -10.3x | -6.96x | -9.72x | -9.67x | -11.8x |
| PBR | - | - | - | 2.25x | 3.43x | 5.38x | 5.18x | 5.54x |
| PEG | - | -0.4x | -0.6x | 0.6x | -0.1x | -1.38x | -17.77x | 0.7x |
| Capitalization / Revenue | 388x | 891x | 315x | 239x | 1,168x | 1,603x | 267x | 24.9x |
| EV / Revenue | 300x | 761x | 254x | 136x | 832x | 1,269x | 214x | 20.3x |
| EV / EBITDA | - | - | -11.3x | -4.96x | -4.53x | -7.96x | -7.99x | -11.9x |
| EV / EBIT | -19.6x | -15.6x | -12.3x | -4.88x | -4.48x | -7.5x | -7.01x | -8.61x |
| EV / FCF | -22.4x | -17x | -16x | -5.96x | -6.02x | -9.08x | -9.26x | -13.6x |
| FCF Yield | -4.46% | -5.88% | -6.25% | -16.8% | -16.6% | -11% | -10.8% | -7.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.64 | -2.4 | -2.92 | -2.45 | -3.9 | -4.174 | -4.196 | -3.444 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.651 | 2.357 | 6.883 | 7.02 | 1.545 | 1.988 | 11.92 | 127.9 |
| EBITDA 1 | - | - | -154.5 | -191.9 | -284 | -316.9 | -318.9 | -218.5 |
| EBIT 1 | -71.24 | -115.2 | -142 | -195.1 | -287.4 | -336.4 | -363.7 | -301 |
| Net income 1 | -70.51 | -112.3 | -141.4 | -157.9 | -258.8 | -317.2 | -355.1 | -322.4 |
| Net Debt 1 | -408.2 | -305 | -423.6 | -725.3 | -518.6 | -662.3 | -637.6 | -595.4 |
| Reference price 2 | 38.64 | 44.57 | 39.66 | 25.27 | 27.16 | 40.57 | 40.57 | 40.57 |
| Nbr of stocks (in thousands) | 46,664 | 47,100 | 54,689 | 66,344 | 66,449 | 78,530 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 2/27/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.72x | 1269.37x | -7.96x | -.--% | 3.19B | |
| 34.52x | 6.15x | 18.3x | 0.93% | 51.21B | |
| -21.75x | 300.18x | -21.99x | -.--% | 45.35B | |
| 33.51x | 3.25x | 14.04x | -.--% | 42.84B | |
| 48.73x | 5.66x | 30.94x | -.--% | 42.29B | |
| 29.46x | 8.52x | 21.53x | 0.39% | 32.15B | |
| 35.26x | 5.79x | 26.29x | -.--% | 17.31B | |
| 24.42x | 2.12x | 9.17x | 1.1% | 14.84B | |
| 79.87x | 4.18x | 16.23x | -.--% | 14.25B | |
| Average | 28.26x | 178.36x | 11.84x | 0.27% | 29.27B | |
| Weighted average by Cap. | 27.73x | 71.43x | 12.67x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLDX Stock
- Valuation Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
